The effect of ultrasound-guided subacromial-subdeltoid bursa combined with long head of the biceps tendon sheath corticosteroid injection for hemiplegic shoulder pain

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047125

Enrollment

Unknown

Registered

2021-06-08

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemiplegic Shoulder Pain

Interventions

1 group:Corticosteroid injection into thesubacromial-subdeltoid bursa

2 group:Subacromial-subdeltoid bursa and long head of the biceps tendon sheath corticosteroid injection

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Stroke within 1 to 12 months of onset; 2.Aged 18 to 75 years; 3.Ultrasonographic findings subacromial bursa thickness > 2mm or liquid dark area with no echo > 2mm, the formation of effusion in tendon sheath of brachii biceps longcephalis tendon, or the tendon shape became round and increased, and there was no echo around the liquid dark area; 4Physical examination: the tenderness of biceps sulcus was positive for Neer's sign (+) and Yergason sign. 5.Visual analog scale (VAS) of shoulder pain >= 3 score; 6.MMSE > 20, to ensure the patients can make their own decision to participate in the research and report changes in pain; 7.Patients had received SASD bursa and (or) LHBT sheath corticosteroid injection;

Exclusion criteria

Exclusion criteria: 1.Poorly controlled diabetes (HbA1c > 7.0); 2.The presence of another obvious explanation for the pain (ie, fracture, radiculopathy, myofascial pain, central neuropathic pain); 3.Local infection after injection; 4.The presence of an unstable medical condition or a known uncontrolled systemic disease, including cancer, rheumatoid arthritis, endocrine disease, major depression, or schizophrenia; 5.Incapable of communication owing to severe aphasia and cognitive deficits; 6.Ashworth grade 3 and grade 4 for improved critical muscle strength of the affected upper limb; 7.History of allergies to compound betamethasone (tiboasone) and lidocaine.

Design outcomes

Primary

Measure	Time frame
visual analogue scale;	—

Secondary

Measure	Time frame
passive motion of painless shoulder joint;the upper extremity Fugl-Meyer Assessment (FMA);improved barthel index score;	—

Countries

China

Contacts

Public ContactHou Yajing

Fuxing Hospital, Capital Medical University

15911173973@163.com+86 15911173973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026